Hindustan Bio Sciences Limited

As of June 30, 2026, Hindustan Bio Sciences Limited carries a market capitalization of 73.60M, placing it among publicly traded companies globally. Its enterprise value stands at 73.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hindustan Bio Sciences Limited has 10.25M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 19.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 73.60M versus a market cap of 73.60M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.91M in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Hindustan Bio Sciences Limited's stock has declined approximately 5.35% over the past 52 weeks. The 50-day moving average sits at 7.28, while the 200-day moving average is 7.62.

Over the twelve months ended June 30, 2026, Hindustan Bio Sciences Limited generated 3.83M in revenue and converted that into -2.06M in net income, yielding earnings per share of -0.20. EBITDA reached -2.12M, while operating income came in at -2.32M.

Over the twelve months ended June 30, 2026, Hindustan Bio Sciences Limited posted a gross margin of 38.01, reflecting its pricing power and cost economics. The operating margin of -60.68 and net profit margin of -53.86 provide insight into operational efficiency.